Moreover, J&J believes 10 of its new Innovative Medicine products, including new cancer drugs like Talvey and Tecvayli, and pipeline candidates, like nipocalimab and icotrokinra (JNJ-2113), have ...

SPRING HOUSE, Pa., (April 30, 2025) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved IMAAVY™ (nipocalimab-aahu), a human FcRn-blocking ...

The FDA Wednesday approved nipocalimab-aahu (Imaavy; Johnson & Johnson) for the treatment of generalized myasthenia gravis (gMG) in adults and pediatric patients 12 years or older who are anti ...

Nipocalimab led to sustained MG-ADL and QMG ... paying a 9% dividend—before Wall Street catches on. Johnson & Johnson JNJ on Tuesday announced results from additional analyses of the Phase ...

JNJ) announced today that 12 abstracts, including two oral presentations, highlighting the Company's innovative autoantibody disease research and the potential of nipocalimab to provide long-term ...

Johnson & Johnson JNJ announced that the FDA has granted a Fast Track designation (“FTD’) to its investigational drug, nipocalimab, for treating adult patients with moderate-to-severe Sjögren ...

Johnson & Johnson (NYSE:JNJ) said on Tuesday that it received U.S. FDA's Fast Track designation for nipocalimab to treat adult patients with moderate-to-severe Sjögren's disease. In November last ...

March 18, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted investigational nipocalimab Fast Track designation (FTD ...